The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

A widely prescribed diabetes drug may be sabotaging one of the most trusted strategies for preventing the disease: exercise.

Three new studies shed light on some common questions about atrial fibrillation: whether your morning coffee matters, whether ...

The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

Overall, the study concludes that metformin may limit some of the vascular and metabolic benefits of exercise, affecting both ...

Rutgers scientists found that metformin can blunt many of the metabolic and cardiovascular improvements normally produced by ...

The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect of Bayer's top selling cancer drug, ...

Galmed Pharmaceuticals ( ($GLMD) ) has shared an update. Galmed Pharmaceuticals announced on November 17, 2025, the top-line results of their ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today ...

The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect ...

This research builds on previous findings from May 2025, when Galmed reported that Aramchol significantly enhanced regorafenib’s ability to kill gastrointestinal tumor cells in various cancer models.

Tens of millions of people with type 2 diabetes might actually be undermining their efforts to improve their health, with researchers demonstrating that the commonly prescribed metformin blocks the ...